Cargando…

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

OBJECTIVE: To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. RESEARCH DESIGN AND METHODS: Post hoc analysis of over 2,000 metabolic syndrome patients administered either FA +...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bays, Harold E., Roth, Eli M., McKenney, James M., Kelly, Maureen T., Thakker, Kamlesh M., Setze, Carolyn M., Obermeyer, Katie, Sleep, Darryl J.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928374/ https://www.ncbi.nlm.nih.gov/pubmed/20573750 http://dx.doi.org/10.2337/dc10-0357

Ejemplares similares

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides
por: Ballantyne, Christie M., et al.
Publicado: (2011)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2010)

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis
por: Jones, Peter H., et al.
Publicado: (2012)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial
por: Davidson, Michael, et al.
Publicado: (2012)

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study
por: Kwon, Taek-Geun, et al.
Publicado: (2020)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
por: Farnier, Michel
Publicado: (2008)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Insights Into Statin Intolerance
por: Kopecky, Stephen, et al.
Publicado: (2015)

Maintaining Cardiovascular Health in Patients With Mixed Dyslipidemia Optimizing the Management of Hypertriglyceridemia and Non-HDL Cholesterol
por: Ito, Matthew, et al.
Publicado: (2009)

Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy
por: Grandi, Anna M, et al.
Publicado: (2014)

The role of dyslipidemia and statins in venous thromboembolism
por: Ray, Joel G, et al.
Publicado: (2001)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
por: Azar, Sami T, et al.
Publicado: (2014)

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
por: Filippatos, Theodosios D.
Publicado: (2012)

New Drugs for Treating Dyslipidemia: Beyond Statins
por: Ahn, Chang Ho, et al.
Publicado: (2015)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
por: Kim, Nam Hoon, et al.
Publicado: (2019)

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

Prevalence and types of persistent dyslipidemia in patients treated with statins
por: Reiner, Željko, et al.
Publicado: (2013)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
por: Bak, Keunhyeong, et al.
Publicado: (2023)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia
por: Pruski, Maciej, et al.
Publicado: (2009)

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
por: Meikle, Peter J., et al.
Publicado: (2015)

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
por: Benes, Lane B, et al.
Publicado: (2016)

Detecting responses to treatment with fenofibrate in pedigrees
por: Cherlin, Svetlana, et al.
Publicado: (2018)

The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes
por: Shinnakasu, Atsushi, et al.
Publicado: (2017)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
por: Alwhaibi, Monira, et al.
Publicado: (2019)

Treatment of Dyslipidemia with Statins and Physical Exercises: Recent Findings of Skeletal Muscle Responses
por: Bonfim, Mariana Rotta, et al.
Publicado: (2015)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
por: Castaldo, Richard S.
Publicado: (2016)

Fibrane the reduced derivative of fenofibrate
por: Kotheimer, Amanda E., et al.
Publicado: (2019)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential()()
por: Stalinska, J., et al.
Publicado: (2019)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_62ri56tb252dgmi3dm9i5bt9su